Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $223.00.

A number of research analysts have recently commented on KRYS shares. Chardan Capital dropped their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. HC Wainwright restated a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Citigroup reiterated a “neutral” rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Bank of America lifted their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th.

Krystal Biotech Stock Up 2.0%

KRYS opened at $189.93 on Tuesday. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $207.84. The company’s 50-day moving average price is $165.86 and its two-hundred day moving average price is $152.11. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of 38.60 and a beta of 0.64.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. As a group, sell-side analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Institutional Trading of Krystal Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after purchasing an additional 432 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Krystal Biotech in the first quarter worth about $229,000. New York State Teachers Retirement System lifted its holdings in shares of Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company’s stock worth $2,881,000 after buying an additional 100 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Krystal Biotech by 2.3% in the first quarter. Principal Financial Group Inc. now owns 126,337 shares of the company’s stock valued at $22,779,000 after acquiring an additional 2,884 shares during the period. Finally, GF Fund Management CO. LTD. grew its stake in Krystal Biotech by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 736 shares of the company’s stock valued at $133,000 after acquiring an additional 132 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).